{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sumpio BJ"],"funding":["NIDDK NIH HHS","NIGMS NIH HHS"],"pagination":["435-445"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11535488"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(9)"],"pubmed_abstract":["<b>Introduction:</b> Diabetes mellitus (DM) affects over 422 million people globally. Patients with DM are subject to a myriad of complications, of which diabetic foot ulcers (DFUs) are the most common with ∼25% chance of developing these wounds throughout their lifetime. <b>Innovation:</b> Currently there are no therapeutic RNAs approved for use in DFUs. Use of dressings containing novel layer-by-layer (LbL)-formulated therapeutic RNAs that inhibit PHD2 and miR-210 can significantly improve diabetic wound healing. These dressings provide sustained release of therapeutic RNAs to the wounds locally without systemic side effects. <b>Clinical Problem Addressed:</b> Diabetic foot wounds are difficult to heal and often result in significant patient morbidity and mortality. <b>Materials and Meth"],"journal":["Advances in wound care"],"pubmed_title":["Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds."],"pmcid":["PMC11535488"],"funding_grant_id":["F30 DK130564","T32 GM144273"],"pubmed_authors":["Li Z","Johnston BH","Sumpio BJ","Dallas A","Wang E","Mezghani I","Berger AG","Ilves H","Veves A","Contreras M","Hammond PT","Theocharidis G"],"additional_accession":[]},"is_claimable":false,"name":"Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds.","description":"<b>Introduction:</b> Diabetes mellitus (DM) affects over 422 million people globally. Patients with DM are subject to a myriad of complications, of which diabetic foot ulcers (DFUs) are the most common with ∼25% chance of developing these wounds throughout their lifetime. <b>Innovation:</b> Currently there are no therapeutic RNAs approved for use in DFUs. Use of dressings containing novel layer-by-layer (LbL)-formulated therapeutic RNAs that inhibit PHD2 and miR-210 can significantly improve diabetic wound healing. These dressings provide sustained release of therapeutic RNAs to the wounds locally without systemic side effects. <b>Clinical Problem Addressed:</b> Diabetic foot wounds are difficult to heal and often result in significant patient morbidity and mortality. <b>Materials and Meth","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-05-29T18:45:57.027Z","creation":"2026-04-08T05:43:12.536Z"},"accession":"S-EPMC11535488","cross_references":{"pubmed":["38183631"],"doi":["10.1089/wound.2023.0056"]}}